Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
BURLINGTON, Mass., July 03, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will hold an Investor and Analyst Day on Monday, July 10, 2017. Flexion executives will discuss plans for commercializing Zilretta™ (FX006), the company’s lead investigational product candidate for the treatment of osteoarthritis knee pain. Management will also provide an update on the company’s pipeline, and they will be joined by two medical experts who will present important clinical perspectives on Zilretta.
Event Details
Date: Monday, July 10, 2017
Time: 10:00 a.m. – 12:00 p.m. EDT
The presentation will be accessible via live webcast at: http://edge.media-server.com/m/p/a5pnvdm8. A replay will also be available on the company’s website.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
